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Abstract
Aim: Glucagon is an essential regulator of hepatic glucose production (HGP), which provides an alternative therapeutic
target for managing type 2 diabetes with glucagon antagonists. We studied the effect of a novel human monoclonal
antibody against glucagon receptor (GCGR), NPB112, on glucose homeostasis in diet-induced obese (DIO) mice.
Methods: The glucose-lowering efficacy and safety of NPB112 were investigated in DIO mice with human GCGR for 11
weeks, and a hyperinsulinemic-euglycemic clamp study was conducted to measure HGP.
Results: Single intraperitoneal injection of NPB112 with 5 mg/kg effectively decreased blood glucose levels in DIO mice for
5 days. A significant reduction in blood glucose was observed in DIO mice treated with NPB112 at a dose $5 mg/kg for 6
weeks, and its glucose-lowering effect was dose-dependent. Long-term administration of NPB112 also caused a mild 29%
elevation in glucagon level, which was returned to the normal range after discontinuation of treatment. The clamp study
showed that DIO mice injected with NPB112 at 5 mg/kg were more insulin sensitive than control mice, indicating
amelioration of insulin resistance by treatment with NPB112. DIO mice treated with NPB112 showed a significant
improvement in the ability of insulin to suppress HGP, showing a 33% suppression (from 8.3 mg/kg/min to 5.6 mg/kg/min)
compared to the 2% suppression (from 9.8 mg/kg/min to 9.6 mg/kg/min) in control mice. In addition, no hypoglycemia or
adverse effect was observed during the treatment.
Conclusions: A novel human monoclonal GCGR antibody, NPB112, effectively lowered the glucose level in diabetic animal
models with mild and reversible hyperglucagonemia. Suppression of excess HGP with NPB112 may be a promising
therapeutic modality for the treatment of type 2 diabetes.
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Introduction
Though type 2 diabetes (T2D) is a multifactorial syndrome of
metabolic dysregulation, current pharmacologic strategies for T2D
are focused on the progressive decline in pancreatic b-cell
functions with diminished tissue responses to insulin (insulin
resistance), closely linked with abnormalities in carbohydrate, fat,
and protein metabolism [1]. In normal glucose and type 2 diabetic
conditions, insulin secretory function of b-cells in response to
surged carbohydrate from meal loading, and peripheral insulin
sensitivity are main gluco-insulin axis [2]. It is well known that
impaired a-cell function can lead to excessive glucagon release
during postabsorptive and fasting states, which contributes to the
development and progression of hyperglycemia [3]. In this regard,
a therapeutic approach to overcome the uncontrolled excessive
postabsorptive and fasting hepatic glucose production (HGP) as
well as insulin resistance in the context of progressive islet
dysfunction leading to hyperglycemia [4] might be more
physiologic to achieve glycemic control.
In type 2 diabetics, the metabolic homeostasis in glucose and
glucagon are largely characterized by high a-cell secretion of
plasma glucagon, especially in subjects with poorly controlled and
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insulinopenic status [5] or impaired counter-regulatory response of
glucagon to hypoglycemia [6]. These inappropriate balances
between postabsorptive and fasting glucagon secretion drive
excessive HGP in T2D. However, therapeutic modalities targeting
the underlying defects in oversecretion of glucagon that cause
these abnormal physiologic responses have not been well
investigated. To date, several glucagon antagonists have been
reported to regulate glucagon-mediated signal pathway in diabetic
animals. Treatment with non-peptide compounds that antagonize
GCGR inhibited hepatic glucose production and decreased blood
glucose levels [7,8]. Antisense oligonucleotides significantly
improved glucose tolerance and hyperglycemia in various diabetic
models such as db/db, ob/ob mice and ZDF rats [9,10]. Recently,
monoclonal antibodies targeting GCGR have been also developed
to achieve improvement in glycemic control [11–13]. Although
many reports with glucagon antagonists showing glucose-lowering
efficacy in various animal models have been published, there is no
clinically available glucagon antagonists for humans with diabetes
so far, indicating that continuous efforts are highly required to
develop novel drugs targeting glucagon signaling pathways.
The current report describes a series of studies designed to
examine the effects of treatment with a novel, human monoclonal
antibody against glucagon receptor (GCGR) on glucose reduction
as well as the metabolic consequences and mechanism of potential
compensatory responses stemming from GCGR antibody treat-
ment.
Materials and Methods
Establishment of Recombinant Cell Lines Expressing
GCGR
Stable cell lines expressing GCGR were established according
to similar procedures described previously [11]. Briefly, recombi-
nant GCGR cDNAs originating from murine, cynomolgus
monkey, and human were subcloned into expression vector
plasmids containing a selectable antibiotic gene. After transfected
cells were subcloned under appropriate antibiotic selection,
glucagon-induced cyclic AMP accumulation and specific 125I-
glucagon binding were measured for screening.
The cell line expressing a high level of hGCGR was developed
by transfecting a CMV promoter-driven expression vector with
full-length hGCGR cDNA into AM1D cells. GCGR mRNA level
and specific 125I-glucagon binding were then measured to select a
stable subclone. After an expression construct was created by
combining hGCGR with human recombinant GFP (Stratagene,
La Jolla, CA, USA) at the C-terminus, a stable cell line with
hGCGR-GFP was generated in 293T cells (293-HEK-hGCGR-
GFP cells). FACS was performed to select and enrich transfected
cells with high expression of GFP.
Development and Selection of Anti-GCGR Antibodies
To produce high-affinity human monoclonal antibodies to the
hGCGR from XenoMouseH(Amgen British Columbia, Inc,
Burnaby, BC), we chose to use the N-terminal extracellular
domain of the GCGR fused to an Fc fragment, whole-cell
membranous fractions from GCGR-expressing cell lines, and
peptides corresponding to the extracellular regions. Supernatants
of hybridomas were tested for specific binding to hGCGR using
fluorometric microvolume assay technology. In total, 122 mono-
clonal antibodies that proved to be bound specifically to hGCGR
were initially selected. Crude hybridoma supernatants of the
specific antibodies were screened for their ability to suppress
glucagon-induced cAMP production in hGCGR recombinant
cells. Antibodies with antagonistic activities were isolated from
supernatants, and inhibitory properties were investigated at a
2 mM final concentration. We used phage display methods using
immuno-tube to generate and select specific anti-GCGR antibod-
ies. The surface of each immuno-tube was coated with either
positive or negative antigen against hGCGR (1 mL at concentra-
tion of 10 mg/mL) at 37uC for 1 hr. Then libraries were blocked
with solution of 2% skim milk in PBS (MPBS) to adjust the titer of
those into the concentration of 1011 CFU/mL. Antigen-coated
immuno-tubes were also blocked with MPBS for 1 hr at room
temperature. Each library blocking solution was transferred into
negative antigen-coated immuno-tubes and incubated for 1 hr at
room temperature after MPBS was removed from those tubes.
Then, library blocking solution from negative antigen-coated tubes
was transferred into MPBS removed immuno-tubes coated with
positive antigen and incubated for 1 hr at room temperature. After
removal of library blocking solution, positive antigen-coated
immuno-tubes were washed with MPBS for twice and PBST
(0.05% tween 20) for 7 times, followed by repeated washing with
PBS for 3 times to eliminate unbound phage libraries from the
tube. Washed tubes were eluted with 1 mL 100 mM TEA (pH 12)
for 10 min at room temperature and neutralized with 150 uL 1 M
Tris-HCl (pH 7.4). Eluted phage was infected into 10 mL XL1
Blue (Escherichia coli) at 37uC for 1 hr and the culture was
centrifuged at 5000g for 15 min at room temperature. The pellet
was resuspended in 900 mL 2TY phage medium and spread in
agarose plates for overnight incubation at 37uC. A colony from a
streaked 2TY agarose plate of XL1 Blue was inoculated into
50 mL 2TY medium and grown overnight at 37uC. When an
optical density 600 nm (OD600) of 0.8 is reached, helper phage
(M13-K07) was infected into the culture and incubated at 37uC for
1 hr with shaking (at 100 rpm). After centrifuge at 5000 g, pellets
were resuspended into 50 mL 2TY medium and grown overnight
at 33uC. Supernatant was isolated after centrifuge at 12,000 g for
15 min and second round panning was repeatedly conducted with
using this supernatant. When performing second round panning,
selected single colony was inoculated into 96 well plates and high
affinity antibodies with positive antigen were determined by using
ELISA methods [14]. NPB112 was subsequently cloned for
recombinant expression as human IgG2.
Antibody Activity Assay: cAMP Assay
After resuspension of 293-HEK-hGCGR-GFP cells at 5610
cells/ml in assay buffer (PBS+0.1% bovine serum albumin) with
1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich, St.
Louis, MO), the cell suspension was mixed with cAMP-d2 working
solution containing lyophilized powder dissolved in distilled water.
Serially diluted test antibodies were added to recombinant cells
and incubated at 37uC for 20 min. Cells were treated with fresh
glucagon solution (Bachem, Bubendorf, Switzerland) at a final
concentration of 50 pM in the presence of IBMX and incubated at
37uC for 20 min. The cell stimulation was stopped by adding an
equal amount of lysis buffer containing cAMP-XL665 and anti-
cAMP-cryptate. After shaking the plate for 1 h at room
temperature, the cAMP levels were quantified using a Cisbio
cAMP dynamic 2 kit (Cis Bio International, Gif-sur-Yvette,
France). The homogeneous time-resolved fluorescence (HTRF)
2-step protocol was performed according to the manufacturer’s
instructions, and the RUBYstar (BMG Labtech, Durham, NC)
instrument was used to detect the HTRF signal. Nonlinear
regression analyses of resulting concentration curves were plotted
using GraphPad Prism (GraphPad Software, Inc., San Diego, CA).
Antibody affinity assay: cell ELISA. Ninety-six wells were
coated with test antibodies (anti-human Lambda antibodies) by
adding the solution at a concentration of 2 mg/ml in PBS to each
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well, and the plates were incubated overnight at 4uC. Standard
human IgG was used as the internal control. Plates were then
blocked with 100 ml of 2% milk in PBS for 1 h at room
temperature. Then, 293-HEK-hGCGR-GFP cells were added
into each well, incubated for 1 h at 37uC and then washed 3 times
with PBS-0.01% Tween. Anti-human IgG-horseradish peroxidase
(HRP) conjugate (1:10000, Sigma-Aldrich, SL) was added to the
plate and incubated for 1 h at room temperature. After washing 3
times with PBS-0.01% Tween, plates were filled with 50 ml of
TMB substrate (Kirkegaard and Perry Laboratories, KPL,
Gaithersburg, MD) solution according to the manufacturer’s
instructions and measured on the luminometer (SPECTRA max
340PC, Molecular Devices Corporation, Sunnyvale, CA).
Pharmacokinetic analysis. The pharmacokinetics of
NPB112 were conducted in male Sprague-Dawley (SD) rats of
which right jugular veins were cannulated with catheters. A total
of 10 rats were divided into two groups (n = 5, each) and NPB112
at 5 mg/kg was intravenously or intraperitoneally administered
into each group, respectively. Blood samples for pharmacokinetic
analysis were collected from each animal in the 5 mg/kg dose
groups on 6 hours and days 1, 2, 3, 4, 5, 6, 7, and 10. The
concentrations of NPB112 in plasma samples were measured by a
sandwich enzyme-linked immunosorbent assay using rabbit anti-
human-lambda antibodies and horseradish peroxidase-conjugated
mouse anti-human IgG antibodies. Pharmacokinetic parameters
including T1/2 and area under the concentration-time curve
(AUC) were estimated from NPB112 plasma concentration data
via noncompartmental analysis using KineticaTM software version
4.4.1 (Pharsight, Mountain View, CA) and the linear/logarithmic
trapezoidal method.
Animals and diets. All mouse experiments were conducted
at NeoPharm Co., LTD. (Daejon, Korea), and all procedures were
approved by the Institutional Animal Care and Use Committee
named ‘‘Neopharm an animal experiment committee’’ (The
animal experiment identification number 33th). All mice were
anesthetized by intraperitoneal injection with 0.1cc/100g zoletil.
Twelve–week–old male C57BL/6N mice with human GCGR
were obtained from the Institute of Medical Science, University of
Tokyo (Japan). The mice were maintained at ambient temperature
(22uC 61uC) with 12-hour light-dark cycles and free access to
water and food. Human GCGR mice were fed a 60% kcal% fat
diet (HFD, D12492, Research Diets, NJ) for 8 weeks to induce
obesity. The composition of the HFD was approximately
5.24 kcal/g, and the relative amounts were 26.2 gm% protein,
26.3 gm% carbohydrate and fat 34.9 gm% fat.
Glucose Tolerance Tests
An intraperitoneal glucose tolerance test (IPGTT) was per-
formed after an overnight fast for 14 hours in the hGCGR mice at
20 weeks of age. NPB112 at a dose of 5.0 mg/Kg was injected in
each mouse 48 hours before the IPGTT. After 1 g/kg of glucose
was intraperitoneally injected, blood glucose levels were measured
at 30, 60, 90 and 120 min using a glucose analyzer (Accu-Check;
Roche Diagnostics, Basel, Switzerland).
Efficacy Studies in hGCGR Mice with HFD
1) Effect of short-term treatment with NPB112 on glucose
reduction and body weight changes.
Before starting the NPB112 injection, blood glucose levels and
body weight were measured in 20-week-old male C57BL/6N mice
fed a HFD for 8 weeks (n = 9) in order to evaluate the short-term
glucose reduction and body weight changes. On day 1 (time 0), all
mice were bled for blood glucose measurement and were injected
intraperitoneally with vehicle or NPB112 at 1.2 and 5 mg/kg at
the dose volume of 10 ml/kg. Subsequent blood glucose
measurements (Accu-Check Inform, Roche Diagnostics) were
performed via tail vein collection at 1, 2, 3, 5, and 7 days after
injection.
2) Effect of long-term treatment with NPB112 on glucose
reduction and body weight changes.
To evaluate the 6-week, long-term glucose reduction and body
weight changes, 20-week-old male C57BL/6N mice fed a HFD for
8 weeks were classified into 5 groups. Each group consisted of
24 mice and was administrated vehicle or NPB112 at 0.3 mg/kg,
1.0 mg/kg, 3.0 mg/kg and 10.0 mg/kg, respectively, twice a week
for 6 consecutive weeks (total of 12 injections). After the 6-week
treatment with NPB112, mice were observed for a4 week drug
washout periods. Subsequent measurements of blood glucose and
body weight were performed weekly for 11 weeks. Serum levels of
insulin and glucagon were repeatedly measured at 0, 2, 4, 7, 9 and
11 weeks after treatment.
Hypoglycemia in ICR Mice
To determine whether NPB112 cells induce hypoglycemia in
normal conditions, male ICR mice (Jackson Laboratory, Bar
Harbor, ME) were prepared. ICR mice were randomly assigned at
13 weeks of age into 3 groups; 1) control group treated with vehicle
(150 mL of PBS buffer, n = 7), 2) low dose group with NPB112
(5.0 mg/kg, n = 7), 3) high dose group with NPB112 (10.0 mg/kg,
n = 7). Forty-eight hours after intraperitoneal administration with
the drug or vehicle, ICR mice were fasted for 16 hours. Then,
blood glucose levels were measured using a glucose analyzer
(Accu-Check Inform, Roche Diagnostics).
Biochemical Analyses
Blood samples were obtained by cardiac puncture and
immediately centrifuged at 5000g for 5 minutes. After 0, 2, and
4 weeks from discontinuation of NPB112, levels of aspartate
aminotransferase (AST), alanine aminotransferase (ALT), total
cholesterol, triglycerides, non-esterified fatty acids (NEFA), and
hemoglobin were determined using a HITACHI 7180 automatic
analyzer (Daiichi, Japan). Serum levels of glucagon and insulin
were measured using an ELISA kit (ALPCO Diagnostics, Wind-
ham, NH).
Hyperinsulinemic-euglycemic Clamp Study to Measure
Hepatic Glucose Output
Twelve-week-old male C57BL/6N mice were fed a high-fat diet
for 8 weeks (n = 5 per group). Indwelling catheters were positioned
into the right internal jugular vein extending to the right atrium
and mice were stabilized for 7 days to initiate the hyperinsulin-
emic-euglycemic clamp studies. After mice were fasted during
overnight, [3-3H]glucose (HPLC purified; Perkin Elmer Inc.,
Norwalk, CT) was infused at a rate of 0.05 mCi/min for 2 hours to
examine the basal glucose turnover. Following the basal period,
hyperinsulinemic-euglycemic clamps were operated for 120
minutes with a primed/continuous infusion of human insulin
(100,150 pmol/kg prime, 15,18 pmol/kg/min infusion; Novo
Nordisk, Bagsvaerd, Denmark) in order to raise plasma insulin
levels to within the physiological range. Blood samples (10 ml) were
collected at 10- to 20-minute intervals for the immediate
measurement of plasma glucose, and 20% dextrose was infused
at variable rates to maintain plasma glucose at basal levels
(,6.7 mM). To assess insulin-stimulated whole-body glucose
fluxes, [3-3H]glucose was infused at a rate of 0.1 mCi/min
throughout the clamps, and 2-deoxy-D-[1-14C] glucose (2-
[14C]DG, HPLC purified; PerkinElmer) was injected as a bolus
Human GCGR mAb Improves Glycemic Control in Mice
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e50954
75 minutes into the clamping to estimate the rate of insulin-
stimulated tissue glucose uptake. Blood samples were obtained at
the end of the basal period and during the last 45 minutes of the
clamping to measure plasma [3H]glucose and [14C]glucose
activities. Blood samples were collected repeatedly to measure
plasma insulin concentrations at the end of the basal and clamp
periods. At the end of the clamp experiments, pentobarbital
sodium was injected into mice, and tissues were collected for
biochemical measurements within 4 minutes. Mouse tissues were
dissected and frozen immediately using liquid N2–cooled alumi-
num blocks, and stored at –80uC for subsequent analysis.
Statistical Analyses
Data are presented as mean 6 SEM. Data were compared
using the Student’s t test or analysis of variance using the SPSS
16.0 program (SPSS Institute, Chicago, IL). Statistical significance
was defined as a P-value less than 0.05.
Results
NPB112 is a Fully Humanized Antibody of hGCGR with
Good Affinity and Potent Antagonistic Activity in vitro
Among 122 human monoclonal immunogammaglobulin 2
varieties that have been confirmed to specifically bind to native
hGCGR, NPB112 was identified and selected for further
experiments. To evaluate the affinity to hGCGR and the
antagonistic activity of the antibody, cell-based ELISA and cAMP
assay were performed using a recombinant cell line expressing
hGCGR (293-HEK-hGCGR-GFP cells). Figure 1A shows that
NPB112, designated as Ab8, had the highest binding affinity to
hGCGR with an EC50 of 0.5 nM. NPB112 effectively inhibited
the production of cAMP by glucagon with an IC50 of 3.7 nM
against hGCGR in a cell-based cAMP assay (Figure 1B).
Furthermore, NPB112 demonstrated fairly good antagonistic
activity against glucagon receptors from human, murine, and
cynomolgus monkey (Figure 1C), with IC50s of 1.92, 1.53 and
0.45 nM, respectively. According to the sequence analysis of
NPB112, neither a predicted glycosylation site nor extra cysteine
was found in the variable regions of the antibody (data not shown).
Pharmacokinetic analyses conducted in SD rats showed that both
intravenous and intraperitoneal administration displayed similar
pharmacokinetic properties (Table 1). The mean half-life of
NPB112 was 86.8 h in intraperitoneally injected rats and 49.8 h in
intravenously injected rats with low systemic clearance (0.001 l/
hr/kg). After intraperitoneal administration of NPB112 in rats,
Cmax value was achieved on day 2 (Tmax = 24 h) and peritoneal
bioavailability was fairly good (F = 103.3%).
Effect of Short-term Treatment with NPB112 on Glucose
Reduction in hGCGR Mice with HFD (10 days)
Twenty-week-old diet-induced obese (DIO) mice fed an HFD
for 8 weeks received NPB112 at 1.2 or 5 mg/kg to evaluate
whether NPB112 lowers blood glucose level in vivo. After single
injection of NPB112, glucose levels and body weights were
measured for 7 days in DIO mice. Compared to control mice,
dose-dependent reduction in blood glucose level was observed;
DIO mice treated with the highest dose of NPB112 (5 mg/kg) had
a significant decrease in plasma glucose on the first day after
injection (Figure 2A). Blood glucose level returned to baseline
(glucose level at day 0) at day 3 with a 1.2 mg/kg dose, while the
glucose-lowering effect was maintained for 5 days, returning to
baseline at 7 days, with a 5 mg/kg dose of NPB112. Body weight
was slightly reduced after injection of NPB112; however, there was
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no significant difference in body weight changes during the study
period (Figure 2B).
To investigate the effect of NPB112 on glucose tolerance in
DIO mice, we performed IPGTT in DIO mice on day 2 after a
single subcutaneous injection of NPB112 at a dose of 5 mg/kg.
Figure 2C shows that a 5 mg/kg dose of NPB112 significantly
improved glucose tolerance in DIO mice (P,0.001 versus vehicle-
treated mice at 30, 60, 90, 120 min).
Effect of Long-term Treatment with NPB112 on Glucose
Lowering in hGCGR Mice with HFD (11 weeks)
We then investigated the chronic glucose-lowering effect of
NPB112 in DIO mice. After being fed a HFD for 8 weeks, DIO
mice received NPB112 at 1.0 mg/kg, 3.0 mg/kg and 10.0 mg/kg
twice a week for 6 consecutive weeks (total of 12 injections). The
recovery period with no injection of NPB112 lasted another 4
weeks. The blood glucose level and body weight of DIO mice were
measured once a week for all 11 weeks of the experiment. In terms
of glycemic control, a significant reduction in blood glucose level
was observed in DIO mice treated with a high dose of NPB112
(3.0 and 10.0 mg/kg) during the initial 6 weeks, while blood
glucose level was gradually increased after 6 weeks of treatment
(Figure 3A). The glucose-lowering efficacy of NPB112 in DIO
mice was dose-dependent, and no hypoglycemia was observed in
any animals at any dose of NPB112 throughout the entire
experiment period. With respect to changes in body weight, there
was no significant difference in body weight between control and
experimental groups during the entire treatment period
(Figure 3B). Although DIO mice lost their weight in the first 2
to 3 weeks of experiment, their weight was restored and increased
after 3 weeks including the recovery period.
During the NPB112 injection period from 1 to 6 weeks, insulin
levels were significantly decreased in DIO mice treated with
NPB112 at a 10.0 mg/kg dose compared to control mice
(Figure 3C). As shown in Figure 3D, a 10.0 mg/kg dose of
NPB112 produced a significant 29% elevation in glucagon level
compared to DIO mice treated with vehicle. Despite the decreased
insulin levels and increased glucagon levels in the DIO mice
treated with NPB112 at 10.0 mg/kg, blood glucose levels did not
increase during the experiment. The effect of NPB112 on
secretion of insulin and glucagon in DIO mice was dose-
dependent, while those effects were both abolished after discon-
tinuation of NPB112 administration.
Suppression of Hepatic Glucose Output by NPB112 in
DIO Mice
To independently assess whole-body and hepatic insulin
sensitivities in vivo, we performed a hyperinsulinemic-euglycemic
clamp study including radioisotope-labeled glucose infusion in
DIO mice treated with vehicle or NPB112 at 5.0 mg/kg. Nine-
week-old male hGCCR mice were fed HFD for 8 weeks before the
clamp study, and a single injection of NPB112 (5.0 mg/kg) was
administered to each animal. After 3H-glucose infusion into 12-h
fasted DIO mice, hepatic glucose output and glucose clearance
were measured in DIO mice treated with vehicle or NPB112 at a
dose of 5.0 mg/kg. Consistent with our previous results, fasting
glucose in NPB112-treated mice decreased by 18% compared with
that in control mice.
As shown in Figure 4, control DIO mice treated with vehicle
showed marked insulin resistance with the mean whole-body
glucose infusion rate (GIR) at only 9.0 mg/kg/min. However,
DIO mice with injection of NPB112 at 5.0 mg/kg were more
insulin sensitive than control mice (the baseline whole-body GIR
in the DIO mice with injection of NPB112 at 5.0 mg/kg was
significantly increased), achieving a mean whole-body GIR of
12.0 mg/kg/min. This indicates that administration of NPB112 at
a dose of 5.0 mg/kg provided ,25% protection against HFD-
induced insulin resistance.
With regard to hepatic insulin sensitivity, DIO mice treated
with NPB112 showed a significant improvement in ability of
insulin to suppress hepatic glucose production, demonstrating 33%
suppression (from 8.3 mg/kg/min to 5.6 mg/kg/min) compared
to the 2% suppression (from 9.8 mg/kg/min to 9.6 mg/kg/min)
in control mice. In addition, treatment with NPB112 ameliorated
hepatic insulin resistance induced by HFD in DIO mice, as
reflected by a 15% reduction in basal hepatic glucose output in
DIO mice treated with NPB112 at a dose of 5.0 mg/kg compared
with control mice with vehicle. However, there was no significant
difference in insulin-stimulated rate of whole-body glucose
turnover, whole-body glycolysis, or whole-body glycogen synthesis
between the two groups.
Figure 1. In vitro study of the affinity and functional activity of
antibodies. A. ELISA of the hGCGR-expressing cell line with candidate
antibodies including NPB112 (designated as Ab8). B. Cell-based cAMP
assay using hGCGR-expressing cell lines with candidate antibodies
including NPB112 (designated as Ab8). C. Cell-based cAMP assay with
NPB112 using recombinant cell lines expressing different GCGRs from
human, murine, and cynomolgus monkey. D. Plasma concentration-
time profiles of NPB112 in male Sprague-Dawley rats following a single
intravenous or intraperitoneal administration of 5 mg/kg NPB112. Data
are expressed as mean 6 S.D. (n = 5/time point/group).
doi:10.1371/journal.pone.0050954.g001
Table 1. Pharmacokinetic parameters of NPB112 after single intravenous or intraperitoneal administration of 5 mg/kg NPB112 to
Sprague-Dawley rats.
Intravenous administration
(n=5)
Intraperitoneal administration
(n =5)
Tmax (h) NA 24.060.0
Cmax (ug/ml) NA 28.463.5
AUClast (ugNh/ml) 3354.26802.9 2766.16593.5
Clearance (l/h/kg) 0.00160.0004 NA
T1/2 (h) 49.8628.2 86.8652.8
F (%) NA 103.3645.5
NA: not applicable.
doi:10.1371/journal.pone.0050954.t001
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Investigation of Adverse Effects of NPB112 on
Hypoglycemia and other Laboratory Abnormalities
To evaluate whether NPB112 induces hypoglycemia in normal
conditions, we administrated NPB112 at a dose of 5.0 mg/kg or
10.0 mg/kg in normal ICR mice and measured plasma glucose
levels after a 16-h fast, 48 h after injection of NPB112. ICR mice
treated with NPB112 at 5.0 mg/kg and 10.0 mg/kg had
significant 9% and 11% reductions in fasting plasma glucose
level, respectively (Figure 5A), while no hypoglycemia (,60 mg/
dL in FPG level) was observed in any of the animals.
To evaluate the adverse effect of NPB112 on DIO mice, liver
enzymes such as AST, ALT and lipid profiles were measured 3
times in DIO mice treated with different doses of NPB112 and
vehicle at the baseline, 2 weeks and 4 weeks after completion of
NPB112 injection (during the recovery period). Compared to
control mice treated with vehicle, there was no significant
difference in levels of AST, ALT, total cholesterol, triglycerides
or NEFA in DIO mice treated with different doses of NPB112
(Figures 5B–E).
Discussion
Glucagon is an essential regulator of glucose homeostasis in
both animals and humans. Contrary to the normal physiologic
response (condition), plasma glucagon level is inappropriately
elevated at a comparable level of blood glucose in subjects with
Figure 2. Effect of NPB112 on blood glucose, body weight and GTT in DIO mice. A. Fasting blood glucose levels before (0 day) and after
single injection of vehicle or NPB112 in male DIO mice (n = 9,10 per group). Values are expressed as mean 6 SEM *, p,0.001 compared to control
mice with vehicle. **, p,0.01 compared to control mice with vehicle. B. Body weight before (0 day) and after single injection of vehicle or NPB112 in
male DIO mice (n = 9,10 per group). C. IPGTT performed after a 14-h fast, 2 days after single injection of vehicle or NPB112 in male DIO mice
(n = 8 per group). Blood glucose levels at baseline, 30, 60, 90 and 120 min after glucose administration were measured. Values are expressed as mean
6 SEM *, p,0.001 compared to control mice with vehicle.
doi:10.1371/journal.pone.0050954.g002
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T2D [15], while a-cell responsiveness to glucagon is nearly blunted
or absent. Hyperglucagonemia and abnormal insulin-to-glucagon
ratios observed in subjects with T2D contribute to pathologic
hyperglycemia in both postabsorptive and fasting states by
increasing hepatic glucose production [6,16]. To date, although
a number of drugs have been developed to control various targets
related to the pathway of insulin secretion and insulin resistance,
Figure 3. Effect of NPB112 on levels of blood glucose (A), body weight (B), insulin (C) and glucagon (D) in DIO mice before and
every week after injection of vehicle of NPB112 for 6 weeks and 4 weeks of recovery period (n=24 per group). Values are expressed as
mean SEM (A and D) *, p,0.001 and **, P,0.05 compared to control mice with vehicle. (B and C) *, p,0.01 and **, P,0.05 compared to control mice
with vehicle.
doi:10.1371/journal.pone.0050954.g003
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there is no commercially available medication that effectively
modulates the glucagon-signaling pathway in humans.
In the present study, we developed a potent fully-humanized
monoclonal antibody (NPB112) against GCGR, the 7-transmem-
brane G-protein-coupled receptor (class II or family B), using our
proprietary techniques. Based on the physiologic action of
glucagon, we hypothesized that the antibody against GCGR
might effectively regulate glucagon-related glucose metabolism by
suppressing the hepatic glucose output, resulting in decreasing
glucose level during the fasting state and between meals. To
demonstrate this hypothesis, we adopted the DIO mouse model
with human GCGR in order to avoid interference from other
hormones, such as insulin which is deficient in streptozotocin-
induced type 1 diabetic models or leptin of which metabolism is
impaired in ob/ob or db/db mice models. We therefore investigated
whether (1) NPB112 binds and functionally antagonizes hGCGR
Figure 4. Effect of NPB112 on hepatic and peripheral insulin sensitivity in DIO mice. A. Fasting glucose levels in the hyperinsulinemic-
euglycemic clamp studies before insulin infusion for mice treated with vehicle or NPB112 at 5.0 mg/kg. n= 5 per group. B. Hepatic insulin action as
the percent suppression of basal hepatic glucose production before insulin infusion for mice treated with vehicle or NPB112 at 5.0 mg/kg. n= 5 per
group. C. Hepatic insulin action as the percent suppression of clamp hepatic glucose production after insulin infusion at the rate of 15,18 pmol/kg/
min for mice treated with vehicle or NPB112 at 5.0 mg/kg. The clamp conditions were same as in A. n= 5 per group. D. Steady-state whole-body
glucose infusion rate (GIR) during the last 30 min of the hyperinsulinemic-euglycemic clamp studies in mice treated with vehicle or NPB112 at
5.0 mg/kg. n= 5 per group. *, p,0.01 compared to control mice with vehicle.
doi:10.1371/journal.pone.0050954.g004
Figure 5. Effect of NPB112 on fasting plasma glucose (A) in normal C57B6 mice treated with NPB112 (n=7 per group) and other
laboratory profiles (B–E) in DIO mice before and every week after injection of vehicle or NPB112 for 6 weeks and 4 weeks of
recovery (n=24 per group). Values are expressed as mean 6 SEM *, p,0.001 compared to control mice with vehicle.
doi:10.1371/journal.pone.0050954.g005
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in vitro and in vivo; (2) chronic treatment with NPB112 effectively
lowers in vivo blood glucose level in diabetic animal models; (3)
NPB112 effectively reduces the hepatic glucose output in those
animals; and (4) prolonged treatment with NPB112 leads to
elevation in glucagon or any unexpected adverse reactions
including hypoglycemia or other laboratory abnormalities in
hGCGR mice.
With respect to GCGR antagonist, several previous reports
have demonstrated that GCGR is a plausible target for the
treatment of T2D by using various substances including small-
molecules (compound A, bicyclic peptide, NNC 25-0926)
[7,8,17,18], antisense oligonucleotides [9,10] and monoclonal
antibodies [11–13,19]. The glucose-lowering effect of non-peptide
receptor competitive antagonists, which are orally available, has
been confirmed in various animal models including rodents
[8,18,20,21] and dogs [7]. Furthermore, a non-peptide compound
with antagonistic activity against glucagon was developed and
shown to effectively suppress glucagon-induced glucose production
and subsequent hyperglycemia in normal human subjects [17].
However, traditional drug development with small molecular
antagonists for GCGR has faced technical challenges associated
with efficiency in blocking the ligand-receptor interaction packet
characteristics of the family B GPCRs [22]. Regarding antisense
oligonucleotides, chronic treatment with GCGR antisense oligo-
nucleotides decreased blood glucose level as well as mRNA
expression of GCGR and significantly improved glucose tolerance
in diabetic rodent models such as db/db, ob/ob mice and ZDF rats
[9,10]. The antibody adopted in this study is a fully humanized
monoclonal antibody antagonizing GCGR that offers a minimal
risk of immunogenicity because it only contains antibody
sequences of human origin, although this does raise possible
concerns related to chimeric and humanized antibodies.
With respect to the efficacy and safety of NPB112, we
demonstrated the following findings for this fully human mono-
clonal antibody (human IgG2): (1) NPB112 showed good affinity
as assessed by cell ELISA and high functional activity confirmed
by cAMP assay using a cell line (293-HEK-hGR-GFPcells)
expressing mouse, cynomolgus monkey, and human glucagon
receptors in vitro. Pharmacokinetic studies of NPB112 showed long
period of half-life with low systemic clearance, suggesting an
acceptable pharmacokinetic profile in the rat. (2) Six-week
administration of NPB112 demonstrated a significant reduction
in blood glucose. Despite being inferior to the anti-GCGR
antibody reported by Yan H et al. [22], which maintained
glucose-lowering effects for 8 days, a single intraperitoneal
injection of NPB112 at 5 mg/kg effectively decreased the blood
glucose level in DIO mice for 5 days. After repeated administra-
tion of NPB112 at dose of 3 or 10 mg/kg, the blood glucose levels
were gradually elevated at 3 weeks of treatment, which might be
attributed to the induction of anti-drug antibodies [23]. Because
we injected fully-humanized monoclonal antibodies into DIO
mice, the immune system of these animals would recognize
NPB112 as a xenoantigen which leads to the generation of
antibodies against NPB112 in the bloodstream after certain
periods from initial injection. These findings are rooms for further
experiments to analyze the characteristics of anti-drug antibodies.
In addition, it is noteworthy that chronic treatment with NPB112
induced rather mild (,1.5 fold increase) and reversible hyperglu-
cagonemia in DIO mice. According to previous studies, hyper-
glucagonemia is the inevitable consequence of treatment with
glucagon receptor antagonists [8–13,19,21]. In agreement with
previous studies, 6-week administration of NPB112 in this study
showed a significant reduction in blood glucose and concomitantly
raised circulating glucagon level by 29% in DIO mice with
hGCGR. With respect to changes of a cells which result in
hyperglucagonemia, some studies reports that anti-glucagon
receptor antagonists are known to induce mild to moderate
hypertrophy and hyperplasia of a cells in islets [10,13,21], whereas
the severity of a cells hyperplasia was much higher in GCGR KO
mice [24,25]. In contrast to these findings, the number and size of
a cells were not significantly affected by the treatment with
glucagon receptor antagonists using antisense oligonucleotides or
non-peptide small molecules in several experiments [8,9], although
hyperglucagonemia was still observed. It is likely that blockade of
glucagon signaling might interfere with the negative feedback-
regulating pathway on glucagon secretion in a cells; however, no
explanation has been offered for this mild hyperglucagonemia
induced by NPB112. This might be due to the diversity in affinity
to GCGR or an unidentified functional property of our antibody.
(3) Regarding the effect of glucagon antagonist on weight, 6-week
treatment with NPB112 caused mild body weight loss in DIO
mice. It was reported that absence of glucagon signaling was
associated with decreased body weight and food intake in GCGR
knockout (Gcgr2/2) mice when HFD was challenged [24],
implying a protective role of glucagon antagonists as anti-obesity
agents. In light of the anti-obesity effect of GLP-1 [26], these
findings might be attributed to an increased level of GLP-1 in
blood with reduced gastric emptying in GCGR knockout mice. It
has also been shown that treatment with glucagon receptor
antagonist results in weight loss of DIO mice with no significant
difference compared with control mice [21]. However, there are a
few conflicting reports that GCGR antagonist did not cause
significant weight loss in diabetic rodent models [8,13,19].
Therefore, further experiments regarding the extent of physical
activity and food intake in diabetic animal models treated with
glucagon antagonists should be carried out. (4) No hypoglycemia
was observed in animals during short- and long-term treatment
with NPB112, and even control mice fasted for 16 hours after
injection of NPB112 had no evidence of hypoglycemia. In terms of
adverse effects of NPB112, we did not observe any biochemical
abnormalities such as elevation of AST or ALT level, or
dyslipidemia after chronic treatment with NPB112 in DIO mice.
To date, there are few published data on the adverse reactions
related to glucagon antagonists. Treatment with antisense
oligonucleotide significantly decreased plasma triglyceride levels
as well as liver triglyceride contents in db/db mice and ZDF rats
[10]. Liang et al. reported that a 3-week treatment with antisense
oligonucleotide induced a significant decrease in serum levels of
free fatty acids and triglyceride, while aspartate aminotransferase
level was elevated in db/db mice, which might be linked to fatty
change in the liver after this treatment [9]. Similar reduction in
plasma triglycerides and NEFA was observed in our DIO animal
models. Recent findings that glucagon receptor antagonist
stimulated the fatty acid oxidation pathway [19] and enhanced
insulin sensitivity of diabetic rodent models [19,21] might suggest
amelioration of increased levels of triglyceride and fatty acids in
blood.
With respect to suppression of the hepatic glucose output by
NPB112, DIO mice injected with NPB112 at 5 mg/kg showed a
significant 33% improvement in terms of the ability of insulin to
suppress HGP compared to the level at baseline. To demonstrate
proof-of-concept that glucagon increased glucose level through
HGP, we performed a euglycemic clamp study to clearly show that
a single injection of our monoclonal antibody against GCGR
significantly increased glucose infusion rate (GIR) with suppression
of the rate of basal and clamp HGP, implying amelioration of
peripheral insulin sensitivity in DIO mice. This finding suggests
that the insulin sensitizing action of NPB112 is mainly mediated by
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PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e50954
its inhibition of production of glucose from liver by two major
pathways – glycogenolysis and gluconeogenesis. Similar results
were observed showing that an antibody against GCGR signifi-
cantly reduced the rate of HGP by 45% in a hyperglycemic clamp
study; however, basal HGP was not affected by the GCGR
antibody [19]. This is in contrast to our findings that NPB112
significantly suppressed the basal HGP by 15% as well as the
clamped HGP. Previous studies showed that the glucagon receptor
antagonist, NNC 25-0926, effectively blocked HGP by inhibition
of glycogenolysis in dogs [7]. Consistent with our data, Winzell
et al. demonstrated that NNC 25-0926 significantly increased GIR
in the euglycemic clamp study, indicating improvement of insulin
sensitivity in DIO mice [21]. In this study, the inhibitory effect of
antagonist on HGP was not further investigated, whereas insulin
secretory function in islets was significantly improved after the
treatment.
The present study has some limitations which should be
overcome by further investigations. First, the pharmacokinetic and
pharmacodynamics property of NPB112 were not fully examined.
Second, measurement of blood level of GLP-1 and immunohis-
tochemistry of pancreatic tissues were not performed to investigate
whether NPB112 may stimulate GLP-1 secretion or cause
histologic alterations such as a-cell hyperplasia in the pancreas
and fatty changes in the liver. Third, physical activity and food
intake in hGCGR mice were not analyzed. In addition, it would
be more valuable to add a non-functioning monoclonal antibody
as a negative control instead of using vehicles in the experiment.
In conclusion, human monoclonal antibody against GCGR
significantly improved glucose homeostasis in diabetic mice by
suppressing hepatic glucose output with no hypoglycemia or
adverse events. These findings suggest that this anti-GCGR
antibody could be a promising alternative treatment option for
T2D in humans. Further studies including pharmacokinetics,
pharmacodynamics and experiments with other T2D animal
models are necessary to elucidate the underlying mechanism and
to investigate additional therapeutic effects of NPB112 in T2D.
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